Clinical trials: Advanced Solid Tumors Patients
Neoplasms
Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer
This open label Phase 1 study involves treating subjects with advanced cancer with BAY80-6946 in combination with paclitaxel. It will determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of…
- Trial name
- NCT01411410
- Testing
- Paclitaxel, Copanlisib (BAY80-6946)
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Bayer
CAR, Solid Tumor
CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors
This study is a clinical study of CD276 CAR-T in the treatment of patients with advanced solid tumors. The purpose is to evaluate the safety and effectiveness of targeting CD276 auto-chimeric antigen receptor T cells in the…
- Trial name
- NCT04691713
- Testing
- Targeting CD276 autologous chimeric antigen receptor T cells
- Where
- China
- Volunteers
- 5 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Solid Tumor, Lymphoma
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in…
- Trial name
- NCT03013491
- Testing
- CX-072, ipilimumab, vemurafenib
- Where
- 31 sites in United States, Netherlands and 4 more
- Volunteers
- 196 people
- Sponsor
- CytomX Therapeutics
Advanced Solid Tumors
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study.
- Trial name
- NCT06959706
- Testing
- TGW101
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- Tagworks Pharmaceuticals BV
Advanced Malignant Solid Tumours
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.
This study aims to explore the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB14 as a monotherapy in adult patients with advanced malignant solid tumours.
- Trial name
- NCT06304818
- Testing
- SCTB14
- Volunteers
- 515 people
- Sponsor
- Sinocelltech Ltd.
HER2-expressing or HER2-mutated Locally or Metastatic Solid Tumors
A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-4602 in subjects with HER2-expressing or HER2-mutated locally advanced or metastatic solid tumors.
- Trial name
- NCT06560138
- Testing
- SHR-4602
- Where
- 5 sites in Australia
- Sponsor
- Atridia Pty Ltd.
Neoplasms
AZD5438 in Patients With Advanced Solid Malignancies
Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data from this study in conjunction…
- Trial name
- NCT00088790
- Testing
- AZD5438
- Where
- 2 sites in United States
- Sponsor
- AstraZeneca
Malignant Solid Tumors
Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors
This is a phase I, multicenter, open-label dose escalation and expansion study to evaluate genakumab alone and in combination with tislelizumab in adult patients with advanced solid malignancies.
- Trial name
- NCT05441046
- Testing
- Genakumab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
This phase II trial studies how well ceralasertib, am Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma…
- Conditions
- Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03682289
- Testing
- Ceralasertib, Olaparib, Durvalumab
- Where
- 3 sites in United States
- Volunteers
- 83 people
- Sponsor
- Rahul Aggarwal
Advanced Solid Tumors
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.
- Trial name
- NCT05944224
- Testing
- SPH4336, Cadonilimab
- Where
- 16 sites in China
- Volunteers
- 63 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Advanced Cancer
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
SGX523 is a drug which acts by blocking the function of an enzyme called MET. MET activity may be important in growth and survival of some types of cancer.
- Trial name
- NCT00606879
- Testing
- SGX523 Capsules
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- SGX Pharmaceuticals, Inc.
Advanced Solid Tumor
Study of LM-302 in Patients With Advance Solid Tumors
A Phase I/II Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors
- Trial name
- NCT05161390
- Testing
- LM-302 Injection
- Where
- China
- Volunteers
- 153 people
- Sponsor
- LaNova Medicines Zhejiang Co., Ltd.
Advanced Solid Tumors
FPT155 in Patients With Advanced Solid Tumors
This study is a Phase 1 open-label, first-in-human, multicenter study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity of FPT155 as monotherapy in patients with advanced solid tumors.
- Trial name
- FPT155-001 (NCT04074759)
- Testing
- FPT155, pembrolizumab
- Where
- 12 sites in Australia, South Korea
- Volunteers
- 80 people
- Sponsor
- Five Prime Therapeutics, Inc.
Solid Tumor
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid…
- Trial name
- NCT05494762
- Testing
- BGB-B167, Tislelizumab
- Where
- 8 sites in United States, Australia
- Volunteers
- 55 people
- Sponsor
- BeiGene
Stage III Prostate Carcinoma, Stage IV Prostate Carcinoma
Dose Finding Safety Study of VAL201 in Cancer Patients
Dose finding safety study of VAL201 in cancer patients.
- Trial name
- VAL201-001 (NCT02280317)
- Testing
- VAL201
- Volunteers
- 12 people
- Sponsor
- ValiRx Plc
Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC)
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
This is a global, multi-center, open-label, Phase I/II first-in-human study of XNW27011 monotherapy as an investigational product (IP) in patients with locally advanced and/or metastatic solid tumors who have failed or are…
- Conditions
- Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic
- Trial name
- NCT06792435
- Testing
- XNW27011
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors
RATIONALE: Bortezomib and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with celecoxib may kill more tumor cells.
- Trial name
- NCT00290680
- Testing
- bortezomib, celecoxib
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Medical University of South Carolina
Cancer
Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors
This phase I study will characterize the safety, tolerability, and maximum tolerated dose and dose-limiting toxicity of weekly bolus Topotecan when administered in combination with to different dosing regimens of docetaxel.
- Trial name
- NCT00193570
- Testing
- Topotecan, Docetaxel
- Volunteers
- 20 people
- Sponsor
- SCRI Development Innovations, LLC
Adult Solid Neoplasm
Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)
This phase I trial is studying the side effects and best dose of interferon alfa-2b when given together with vaccine therapy and GM-CSF in treating patients with locally advanced or metastatic cancer that makes CEA.
- Trial name
- NCT00217373
- Testing
- Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine, Recombinant Interferon Alfa-2b, Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
This is an open-label study in advanced solid tumor patients to determine if entrectinib affects the pharmacokinetics of midazolam and any of its pharmacologically active metabolites.
- Trial name
- NCT03330990
- Testing
- Entrectinib, Midazolam Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.